Highest-materiality recent filing
Ascend Wellness shareholders approve reverse stock split (1-for-10 to 1-for-50)
Special meeting Aug 28, 2026: 112,305,378 votes for reverse split, 1,391,090 against, 6,371 withheld.
AWH Q2 2026 revenue $126.1M (+7.9% seq), Adj EBITDA $29.1M; reverse split vote Aug 28
Q2 2026 net revenue $126.1M, up 7.9% sequentially from $116.9M; retail revenue $92.7M (+11.5%).
Ascend Wellness reduces stockholder meeting quorum to one-third of voting power
Board amended bylaws to lower quorum from majority to one-third of outstanding voting power.
Ascend Wellness Q1 net revenue $116.9M, net loss $29.5M, Adj EBITDA $26.3M
Net revenue of $116.9M, down 3% sequentially from Q4 2025; retail $83.1M, wholesale $33.8M.
Ascend Wellness Holdings completes Class B conversion and annual meeting
On May 4, 2026, all 65,000 outstanding Class B shares of Ascend Wellness automatically converted into Class A shares.
Ascend Wellness reports Q4 2025 revenue $120.5M; net loss widens to $48.7M; FY revenue $500.6M
Q4 2025 revenue $120.5M (down 3.4% sequentially); FY2025 revenue $500.6M (down 10.9% YoY).
Ascend Wellness settles arbitration with GTI for $17M, down from $19.7M award
Settlement payment of $17M made to GTI, resolving $19.7M arbitration award from Feb 6.
Ascend Wellness prelim Q4 rev ~$120M, FY rev ~$500M; GTI arbitration award
Q4 2025 net revenue ~$120M, Adjusted EBITDA ~$30M (25% margin); FY 2025 net revenue ~$500M, Adj EBITDA ~$117M (23% margin).
Ascend Wellness loses arbitration to Green Thumb; net award $19.7M
Arbitrator found both Ascend and Green Thumb breached purchase-obligation agreement from June 2018.
Ascend Wellness Q3 2025: net loss $25.8M, adj EBITDA $31.1M (24.9% margin), revenue $124.7M
Net revenue $124.7M, down 2% sequentially; retail $83.8M (-3.1%), wholesale $41.0M (+0.3%).
Ascend Wellness Q2 revenue $127.3M flat; net loss widens to $24.4M
Net revenue $127.3M, flat QoQ (down 0.5%); retail revenue up 2.5% to $86.5M, wholesale down 6.4%.
Ascend Wellness issues $50M 12.75% senior secured notes due 2029 to repay credit facility
Issued $50M aggregate principal of 12.75% senior secured notes due 2029 at 97.5% of face value.
Ascend Wellness Q1 2025 net revenue $128M, Adj EBITDA $27M, cash from ops positive $5.9M
Net revenue of $128.0M; Adjusted EBITDA of $27.0M (non-GAAP); Adjusted Gross Margin 40.8%.
All six board nominees (Kurtin, Perullo, Swid, Gold, Brill, Francis) elected; each received over 95 million votes for.
Ascend Wellness Holdings dismisses MGO and appoints Withum as new auditor
MGO dismissed as independent auditor effective March 19, 2025; no adverse opinions or modifications in its reports for 2023 and 2024.
Ascend Wellness Q4 2024 Adj. EBITDA $30.2M; FY revenue $562M (+8% YoY)
FY2024 net revenue $562M (+8% YoY); Adj. EBITDA $116M (+9% YoY).
Ascend Wellness issues $15M additional 12.75% senior secured notes due 2029 at 97% of face
Issued $15M of 12.75% senior secured notes due 2029 at 97% face value, plus accrued interest from July 16, 2024.
Ascend Wellness authorizes share buyback of up to 5% of shares or $2.25M
Board approved NCIB effective Jan 2, 2025 to repurchase up to 10,215,690 shares (~5% of outstanding) or $2.25M, whichever is less.
Ascend Wellness repurchases 11M shares (over 5% outstanding) at discount from institutional investor
Repurchased 11,000,000 Class A common shares from an institutional investor in a private transaction, representing over 5% of outstanding shares.
Ascend Wellness Q3 net revenue $141.6M flat YoY; net loss widens to $28.3M, Adj EBITDA down 14.9%
Net revenue $141.6M (+0.3% YoY); retail $93.6M (-7.6% YoY), wholesale $48.0M (+20.1% YoY).
Ascend Wellness replaces CEO and CFO; appoints Samuel Brill as CEO, Roman Nemchenko as CFO
John Hartmann removed as CEO effective Aug 26, 2024; Samuel Brill (formerly Lead Independent Director) appointed CEO.
Ascend Wellness Q2 net revenue $141.5M (+15% YoY); net loss of $21.8M vs prior year net income
Net revenue $141.5M, up 15.1% YoY; gross wholesale revenue +30.1% YoY to $79.6M.
Ascend Wellness closes $235M 12.75% notes due 2029, refinances term loan
Issued $235M senior secured notes at 94.75% of face value, maturing July 16, 2029.
Ascend Wellness issues $235M 12.75% senior secured notes due 2029 to refinance term loan
Private placement of $235M 12.75% Senior Secured Notes due 2029, issued at 94.75% of face value.
Ascend Wellness appoints Julie Francis to board; expands to 7 directors
Julie Francis appointed to Board effective June 3, 2024; board expands from 6 to 7.
Ascend Wellness Q1 net revenue $142.4M (+25% YoY); Adj. EBITDA $32.5M (+39% YoY)
Gross revenue $174.2M (+23.4% YoY); net loss $18.2M vs $18.5M a year ago.
Ascend Wellness transitions Chairman Kurtin and EVP Perullo; separation payments total $5.78M
Abner Kurtin retains Executive Chairman role with $200k salary; $150k RSU; no bonus or severance.
Q4 net revenue $140M (+25% YoY), adjusted EBITDA $32M; first full year positive ops cash flow
Q4 2023 net revenue $140.2M, up 25.0% YoY; full year net revenue $518.6M, up 27.8% YoY.
Ascend Wellness Q3 net revenue $141.3M (+27% YoY); Adj. EBITDA $29.5M up 38.5% QoQ
Net revenue of $141.3M, up 27.0% YoY and 14.9% QoQ; record 6th consecutive quarterly high.
Ascend Wellness reports record Q3 revenue ~$140M, up 15% Q/Q; names Mark Cassebaum CFO
Preliminary Q3 net revenue ~$140M (record, +15% Q/Q).
Ascend Wellness Q2 net revenue $123M (+26% YoY), net income $0.8M vs loss year ago
Net revenue of $123.0M, up 26.1% YoY and 7.7% QoQ; gross revenue $151.0M, up 28.4% YoY.
Ascend Wellness raises $7M via private placement of 9.86M shares at $0.71/share
Issued 9,859,155 shares at $0.71 per share to a single accredited investor for $7M gross proceeds.
Ascend Wellness acquires ~$12M of secured debt of a cannabis operator
Acquired ~2/3 of outstanding secured indebtedness of a cannabis grow, processing, and dispensary operator.
Q1 revenue up 34% to $114.2M; appoints John Hartmann as CEO effective May 15
Net revenue $114.2M (+34.2% YoY); net loss improved to $18.5M from $27.8M.
Ascend Wellness closes acquisition of Devi Holdings for $12M cash and 5.185M shares
Closed acquisition of 100% of Devi Holdings membership interests; total consideration includes $12M cash (subject to adjustments) and 5,185,186 Class A shares.
Ascend Wellness Q4 net revenue $112.1M (+26.7% YoY); Adjusted EBITDA $28.2M
Q4 2022 net revenue $112.1M, up 26.7% YoY; full year net revenue $405.9M, up 22.1% YoY.
Ascend Wellness appoints Joshua Gold and Daniel Neville to board; Paxhia resigns
Joshua Gold appointed as independent director, chair of Audit Committee and member of Compensation and Corporate Governance Committee.
Ascend Wellness Q3 net revenue $111.2M (+14% QoQ); adjusted EBITDA $27.8M, 25% margin, +354bps
Net revenue $111.2M, up 14.1% QoQ and 17.9% YoY; gross revenue $134.3M.
Compensation Committee investigation into Executive Chairman completes; no action
Compensation Committee investigation into allegations against Executive Chairman Abner Kurtin completed; no action warranted.
Ascend Wellness appoints Interim Co-CEOs Perullo and Neville; Kurtin becomes Executive Chairman
Frank Perullo (President) and Daniel Neville (CFO) appointed Interim Co-CEOs effective Sept 27, 2022.
Director Joseph Hinrichs resigns from Ascend Wellness board effective Sept 14, 2022
Joseph Hinrichs resigned from the Board, Audit Committee, and Compensation and Corporate Governance Committee, effective immediately.
Ascend Wellness terminates proposed MedMen NY acquisition over asset condition concerns
On August 15, 2022, Ascend announced it will not proceed with the non-binding term sheet to acquire MedMen NY, Inc.
Q2 net revenue $97.5M (+14.6% QoQ), Adj. EBITDA margin 21.4%, FY2022 guidance reiterated
Net revenue $97.5M, up 14.6% QoQ and 17.0% YoY; gross revenue $117.7M.
Ascend Wellness closes $28.5M incremental term loan, total debt $275M
Debt bears 9.5% fixed interest, matures August 27, 2025; no scheduled amortization.
Ascend Wellness closes $36.5M incremental term loan, total debt facility now $246.5M
Incremental Commitment of $36.5M added to existing $210M term loan under Credit Agreement dated August 27, 2021.
Ascend Wellness Q1 net rev $85.1M, net loss $27.8M, adj EBITDA $16.4M; PA expansion
Net revenue $85.1M, down 3.8% QoQ but up 28.7% YoY; net loss $27.8M vs $16.5M in Q4 2021.
Ascend Wellness stockholders approve 2021 stock incentive and employee stock purchase plans
Stockholders approved 2021 Stock Incentive Plan with 117.9M for, 291.9K against, 65.2K abstain.
Ascend Wellness settles MedMen dispute; to pay $74M total, $15M extra consideration
Signs term sheet to settle legal dispute with MedMen in NY Supreme Court.
Ascend Wellness completes acquisition of Story of PA CR for $53M (10.2M cash + 12.9M shares)
Total consideration ~$53M: $10.2M cash plus 12.9M AWH Class A common shares.
Ascend Wellness Q4 net revenue down 6.2% QoQ to $88.5M; full year revenue up 131% to $332.4M
Q4 2021 net loss of $16.5M vs. $13.0M in Q3 2021; full year loss of $122.7M includes $32M non-cash IPO interest expense.
the Board appointed Samuel Brill as Chief Executive Officer of the Company and removed him as Lead Independent Director of the Board
John Hartmann no longer serves as Chief Executive Officer of the Company.
the Board appointed Samuel Brill as Chief Executive Officer of the Company and removed him as Lead Independent Director of the Board, while maintaining his appointment as director of the Company, effective immediately.
On May 31, 2024, the board of directors (the “Board”) of Ascend Wellness Holdings, Inc. (the “Company”), upon recommendation of the Compensation and Corporate Governance Committee of the Board, appointed Julie Francis as a director of the Company, effective June 3, 2024
On October 25, 2023, the Company announced that Dan Neville, the Company’s Chief Financial Officer, will be leaving the Company effective November 10, 2023.
On October 25, 2023, the Company announced the appointment of Mark Cassebaum as the new chief financial officer of the Company, effective November 27, 2023.
the Board also appointed Mr. Hartmann as a director of the Company, effective May 15, 2023.
On May 9, 2023, the Company’s board of directors (the “Board”) approved the appointment of John Hartmann as the new chief executive officer of the Company, effective May 15, 2023.
Frank Perullo, a co-founder of the Company, who currently serves as a director, President and Interim Co-Chief Executive Officer of the Company, will continue to serve on the Board, and will transition to a Strategic Advisor role for the Company, focusing on regulatory issues and legalization efforts, effective May 15, 2023.
Emily Paxhia informed the Company that she will be resigning as a member of the Board effective upon the earlier of December 1, 2022 and the appointment of a new independent director to the Board.
the Company appointed Joshua Gold as an independent director
Chairman, Founder and former-CEO Abner Kurtin will transition to the role of Executive Chairman of the Board.
Max materiality 0.85 · Median 0.65 · Most common event earnings